Spots Global Cancer Trial Database for Treatment With ATRA-IV and Depakote in Patients With Advanced Solid Tumor Malignancies

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Treatment With ATRA-IV and Depakote in Patients With Advanced Solid Tumor Malignancies

Official Title: Phase I Trial of ATRA-IV and Depakote in Patients With Advanced Solid Tumor Malignancies

Study ID: NCT00195156

Conditions

Solid Tumor Malignancies

Interventions

ATRA-IV

Depakote

Study Description

Brief Summary: The purpose of this study is to find out the highest tolerated dose of Depakote in combination with liposome encapsulated all-trans retinoic acid (ATRA-IV) in patients with advanced solid tumor malignancies.

Detailed Description: To determine the maximum tolerated dose of Depakote in combination with liposome encapsulated all-trans retinoic acid (ATRA-IV) in patients with advanced solid tumor malignancies. This will be a 2-step dose escalation study. Once the patient starts therapy at a designated dose level, it will not be escalated for that patient. Three patients at each dose level must complete 4 weeks of therapy before escalating to the next higher level. If none of the patients experience dose limiting toxicity (DLT), then 3 new patients will be treated with the next higher dose level.